Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 249

1.

Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study.

Keating MJ, Flinn I, Jain V, Binet JL, Hillmen P, Byrd J, Albitar M, Brettman L, Santabarbara P, Wacker B, Rai KR.

Blood. 2002 May 15;99(10):3554-61.

2.

Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group.

Stilgenbauer S, Zenz T, Winkler D, Bühler A, Schlenk RF, Groner S, Busch R, Hensel M, Dührsen U, Finke J, Dreger P, Jäger U, Lengfelder E, Hohloch K, Söling U, Schlag R, Kneba M, Hallek M, Döhner H; German Chronic Lymphocytic Leukemia Study Group..

J Clin Oncol. 2009 Aug 20;27(24):3994-4001. doi: 10.1200/JCO.2008.21.1128.

PMID:
19597025
3.

Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine.

Rai KR, Freter CE, Mercier RJ, Cooper MR, Mitchell BS, Stadtmauer EA, Santábarbara P, Wacker B, Brettman L.

J Clin Oncol. 2002 Sep 15;20(18):3891-7.

PMID:
12228210
4.

Fludarabine followed by alemtuzumab consolidation for previously untreated chronic lymphocytic leukemia: final report of Cancer and Leukemia Group B study 19901.

Byrd JC, Peterson BL, Rai KR, Hurd D, Hohl R, Perry MC, Gockerman J, Nattam S, Larson RA.

Leuk Lymphoma. 2009 Oct;50(10):1589-96.

PMID:
19863336
5.

Quantitative molecular evaluation of minimal residual disease in patients with chronic lymphocytic leukemia: efficacy of in vivo purging by alemtuzumab (Campath-1H).

Galimberti S, Cervetti G, Cecconi N, Fazzi R, Pacini S, Guerrini F, Manetti C, Caracciolo F, Petrini M.

J Immunother. 2004 Sep-Oct;27(5):389-93.

PMID:
15314547
6.

Phase II study of alemtuzumab in chronic lymphoproliferative disorders.

Ferrajoli A, O'Brien SM, Cortes JE, Giles FJ, Thomas DA, Faderl S, Kurzrock R, Lerner S, Kontoyiannis DP, Keating MJ.

Cancer. 2003 Aug 15;98(4):773-8.

7.

Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia.

Montillo M, Tedeschi A, Miqueleiz S, Veronese S, Cairoli R, Intropido L, Ricci F, Colosimo A, Scarpati B, Montagna M, Nichelatti M, Regazzi M, Morra E.

J Clin Oncol. 2006 May 20;24(15):2337-42.

PMID:
16618945
8.
9.

Routine clinical use of alemtuzumab in patients with heavily pretreated B-cell chronic lymphocytic leukemia: a nation-wide retrospective study in Austria.

Fiegl M, Falkner A, Hopfinger G, Brugger S, Zabernigg A, Bauer F, Haslbauer F, Demirtas D, Grossschmidt P, Tatzreiter G, Gastl G, Greil R; Austrian Collaborative Study Group on Alemtuzumab in Chronic Lymphocytic Leukemia..

Cancer. 2006 Nov 15;107(10):2408-16.

10.

Low-dose subcutaneous alemtuzumab in refractory chronic lymphocytic leukaemia (CLL): results of a prospective, single-arm multicentre study.

Cortelezzi A, Pasquini MC, Gardellini A, Gianelli U, Bossi A, Reda G, Sarina B, Musto P, Barcellini W, Neri A, Deliliers GL.

Leukemia. 2009 Nov;23(11):2027-33. doi: 10.1038/leu.2009.148.

PMID:
19641526
11.

Safety and efficacy of subcutaneous Campath-1H for treating residual disease in patients with chronic lymphocytic leukemia responding to fludarabine.

Montillo M, Cafro AM, Tedeschi A, Brando B, Oreste P, Veronese S, Rossi V, Cairoli R, Pungolino E, Morra E.

Haematologica. 2002 Jul;87(7):695-700; discussion 700.

12.

Filgrastim and alemtuzumab (Campath-1H) for refractory chronic lymphocytic leukemia.

Lin TS, Flinn IW, Lucas MS, Porcu P, Sickler J, Moran ME, Lucas DM, Heerema NA, Grever MR, Byrd JC.

Leukemia. 2005 Jul;19(7):1207-10.

PMID:
15858611
13.

Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL).

Lundin J, Kimby E, Björkholm M, Broliden PA, Celsing F, Hjalmar V, Möllgård L, Rebello P, Hale G, Waldmann H, Mellstedt H, Osterborg A.

Blood. 2002 Aug 1;100(3):768-73.

14.

Pilot experience with continuous infusion alemtuzumab in patients with fludarabine-refractory chronic lymphocytic leukemia.

Ferrajoli A, Wierda WG, LaPushin R, O'Brien SM, Faderl S, Browning ML, Keating MJ.

Eur J Haematol. 2008 Apr;80(4):296-8. doi: 10.1111/j.1600-0609.2007.01023.x.

PMID:
18182081
15.

Alemtuzumab for B-cell chronic lymphocytic leukemia.

Robak T.

Expert Rev Anticancer Ther. 2008 Jul;8(7):1033-51. doi: 10.1586/14737140.8.7.1033. Review.

PMID:
18588450
16.

Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia.

O'Brien SM, Kantarjian HM, Thomas DA, Cortes J, Giles FJ, Wierda WG, Koller CA, Ferrajoli A, Browning M, Lerner S, Albitar M, Keating MJ.

Cancer. 2003 Dec 15;98(12):2657-63.

17.

Alemtuzumab (Campath-1H) in the treatment of chronic lymphocytic leukemia.

Alinari L, Lapalombella R, Andritsos L, Baiocchi RA, Lin TS, Byrd JC.

Oncogene. 2007 May 28;26(25):3644-53. Review.

PMID:
17530018
19.

Cyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemia.

Badoux XC, Keating MJ, Wang X, O'Brien SM, Ferrajoli A, Faderl S, Burger J, Koller C, Lerner S, Kantarjian H, Wierda WG.

Blood. 2011 Aug 25;118(8):2085-93. doi: 10.1182/blood-2011-03-341032.

20.

Multicenter study of subcutaneous alemtuzumab administered at reduced dose in patients with fludarabine-relapsed/refractory chronic lymphocytic leukemia: final analysis.

Bezares RF, Stemelin G, Diaz A, Argentieri D, Zubiaur EL, Garay G, Bartomioli M, Ryser R, Milone G.

Leuk Lymphoma. 2011 Oct;52(10):1936-41. doi: 10.3109/10428194.2011.584991.

PMID:
21718136
Items per page

Supplemental Content

Support Center